Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial
Digital
- Autores:
-
Cukierman-Yaffe, Tali
Gerstein, Hertzel C.
Colhoun, Helen M.
Diaz, Rafael
García-Pérez, Luis-Emilio
Lakshmanan, Mark
Bethel, Angelyn
Xavier, Denis
Probstfield, Jeffrey
Riddle, Matthew C.
Rydén, Lars
Messan Atisso, Charles
Hall, Stephanie
Rao-Melacini, Purnima
Basile, Jan
Cushman, William C.
Franek, Edward
Keltai, Matyas
Lanas, Fernando
Leiter, Lawrence A.
Lopez-Jaramillo, Patricio
Pirags, Valdis
Pogosova, Nana
Raubenheimer, Peter J.
Shaw, Jonathan E.
Sheu, Wayne H-H.
Temelkova-Kurktschiev, Theodora
- Tipo de recurso:
- Article of journal
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Santander
- Repositorio:
- Repositorio Universidad de Santander
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.udes.edu.co:001/6017
- Acceso en línea:
- https://doi.org/10.1016/S1474-4422(20)30173-3
https://repositorio.udes.edu.co/handle/001/6017
- Palabra clave:
- Rights
- closedAccess
- License
- Copyright © 2022 The Authors, Elsevier Inc.
| id |
RUDES2_330e574bc8a60e84f45019975d2f613a |
|---|---|
| oai_identifier_str |
oai:repositorio.udes.edu.co:001/6017 |
| network_acronym_str |
RUDES2 |
| network_name_str |
Repositorio Universidad de Santander |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial |
| title |
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial |
| spellingShingle |
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial |
| title_short |
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial |
| title_full |
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial |
| title_fullStr |
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial |
| title_full_unstemmed |
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial |
| title_sort |
Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial |
| dc.creator.fl_str_mv |
Cukierman-Yaffe, Tali Gerstein, Hertzel C. Colhoun, Helen M. Diaz, Rafael García-Pérez, Luis-Emilio Lakshmanan, Mark Bethel, Angelyn Xavier, Denis Probstfield, Jeffrey Riddle, Matthew C. Rydén, Lars Messan Atisso, Charles Hall, Stephanie Rao-Melacini, Purnima Basile, Jan Cushman, William C. Franek, Edward Keltai, Matyas Lanas, Fernando Leiter, Lawrence A. Lopez-Jaramillo, Patricio Pirags, Valdis Pogosova, Nana Raubenheimer, Peter J. Shaw, Jonathan E. Sheu, Wayne H-H. Temelkova-Kurktschiev, Theodora |
| dc.contributor.author.none.fl_str_mv |
Cukierman-Yaffe, Tali Gerstein, Hertzel C. Colhoun, Helen M. Diaz, Rafael García-Pérez, Luis-Emilio Lakshmanan, Mark Bethel, Angelyn Xavier, Denis Probstfield, Jeffrey Riddle, Matthew C. Rydén, Lars Messan Atisso, Charles Hall, Stephanie Rao-Melacini, Purnima Basile, Jan Cushman, William C. Franek, Edward Keltai, Matyas Lanas, Fernando Leiter, Lawrence A. Lopez-Jaramillo, Patricio Pirags, Valdis Pogosova, Nana Raubenheimer, Peter J. Shaw, Jonathan E. Sheu, Wayne H-H. Temelkova-Kurktschiev, Theodora |
| dc.contributor.researchgroup.spa.fl_str_mv |
Everest |
| description |
Digital |
| publishDate |
2020 |
| dc.date.issued.none.fl_str_mv |
2020-07-01 |
| dc.date.accessioned.none.fl_str_mv |
2022-02-04T19:43:54Z |
| dc.date.available.none.fl_str_mv |
2022-02-04T19:43:54Z |
| dc.type.spa.fl_str_mv |
Artículo de revista |
| dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
| dc.type.content.spa.fl_str_mv |
Text |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/ART |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_6501 |
| status_str |
publishedVersion |
| dc.identifier.doi.none.fl_str_mv |
https://doi.org/10.1016/S1474-4422(20)30173-3 |
| dc.identifier.uri.none.fl_str_mv |
https://repositorio.udes.edu.co/handle/001/6017 |
| url |
https://doi.org/10.1016/S1474-4422(20)30173-3 https://repositorio.udes.edu.co/handle/001/6017 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.citationendpage.spa.fl_str_mv |
590 |
| dc.relation.citationissue.spa.fl_str_mv |
7 |
| dc.relation.citationstartpage.spa.fl_str_mv |
582 |
| dc.relation.citationvolume.spa.fl_str_mv |
19 |
| dc.relation.indexed.spa.fl_str_mv |
Scopus |
| dc.relation.ispartofjournal.spa.fl_str_mv |
The Lancet Neurology |
| dc.rights.eng.fl_str_mv |
Copyright © 2022 The Authors, Elsevier Inc. |
| dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_14cb |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/closedAccess |
| dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
| rights_invalid_str_mv |
Copyright © 2022 The Authors, Elsevier Inc. Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) https://creativecommons.org/licenses/by-nc/4.0/ http://purl.org/coar/access_right/c_14cb |
| eu_rights_str_mv |
closedAccess |
| dc.format.extent.spa.fl_str_mv |
9 p |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
Elsevier |
| dc.publisher.place.spa.fl_str_mv |
Reino Unido |
| dc.source.spa.fl_str_mv |
https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30173-3/fulltext |
| institution |
Universidad de Santander |
| bitstream.url.fl_str_mv |
https://repositorio.udes.edu.co/bitstreams/0630075b-e53e-46c1-b82d-07567c382821/download https://repositorio.udes.edu.co/bitstreams/76aa6b42-7e2d-4f79-bd9d-dd6efe4b1d31/download https://repositorio.udes.edu.co/bitstreams/ad2405e5-1235-4488-950f-88f1d3dacbe1/download https://repositorio.udes.edu.co/bitstreams/efe8977c-d4fe-49ba-991f-ef9dc88a920d/download |
| bitstream.checksum.fl_str_mv |
4ae1ac9c0b77b7400628cf1a76b23373 38d94cf55aa1bf2dac1a736ac45c881c 5dbe86c1111d64f45ba435df98fdc825 6823e8237921a10793d834cf5353bfab |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Universidad de Santander |
| repository.mail.fl_str_mv |
soporte@metabiblioteca.com |
| _version_ |
1814158970831503360 |
| spelling |
Cukierman-Yaffe, Tali5f466c2e-241c-4003-be00-bafda047c319-1Gerstein, Hertzel C.8dbb4c88-f0dd-45f2-8bc4-590f0a1e3c3c-1Colhoun, Helen M.41617f18-e528-4e15-819a-0a30d7feb185-1Diaz, Rafaelf2be4a74-501a-4e63-8bbd-965cbcf8c57b-1García-Pérez, Luis-Emilioea8457d4-02d5-4a8f-9581-1f488c4ef63a-1Lakshmanan, Marke4d26b36-1c41-49d9-9c19-d57fb2109f53-1Bethel, Angelyn4d6d5a02-a84f-4a21-84fa-185cbc44d87f-1Xavier, Denis88c9cf48-fa3b-45c6-be03-2cc79e59289d-1Probstfield, Jeffreycce7af47-ba6b-4280-bbb5-4c0a46da5d7d-1Riddle, Matthew C.d5c956b6-8f40-43ca-83bc-4b130c672a99-1Rydén, Larsfbe7a352-5488-4e8a-866d-b966ed6789b4-1Messan Atisso, Charles42893105-5995-4c81-b612-a885c11a8170-1Hall, Stephanie76425501-41fc-4b68-bd22-1a38e1e3d160-1Rao-Melacini, Purnimac6bbca6d-e0c7-4dbc-96ab-5131f24dd673-1Basile, Jan31df2eea-b661-4757-98a0-111336270810-1Cushman, William C.6e873915-69b2-4696-afa0-6d21bbeb3531-1Franek, Edwardc8fa48cd-c0c0-4e99-ad2b-29843fba16c4-1Keltai, Matyas65c5da4f-dca6-4e4f-aa9e-6c2ff81f2df9-1Lanas, Fernandod22b7fe4-9f1f-4028-a22b-be782ef03d3c-1Leiter, Lawrence A.bcdd3211-40b7-474d-9f6c-8a1051ceb9bf-1Lopez-Jaramillo, Patricio9a71267b-dcb0-4d31-b37d-2d30be58d4d2-1Pirags, Valdisc43a25fe-51ee-4b71-863e-54b03868e125-1Pogosova, Nana0f2fb5e5-6659-4562-96e6-74c03e0c46bf-1Raubenheimer, Peter J.260f749c-e594-4273-a34d-e926010f883c-1Shaw, Jonathan E.bee14056-7326-4051-b756-4d809e9c79f8-1Sheu, Wayne H-H.d377b549-9728-486e-820f-f5e9d3ba834b-1Temelkova-Kurktschiev, Theodoraa08e998d-95f2-4139-ae16-bd8009965b60-1Everest2022-02-04T19:43:54Z2022-02-04T19:43:54Z2020-07-01DigitalBackground Diabetes is an independent risk factor for cognitive impairment. We aimed to investigate the association between the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide and cognitive impairment as an exploratory analysis within the Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND) trial. Methods REWIND is a randomised, double-blind placebo-controlled trial at 371 sites in 24 countries. We included men and women (aged ≥50 years) with either established or newly diagnosed type 2 diabetes and additional cardiovascular risk factors, glycated haemoglobin of up to 9·5% (80 mmol/mol) on a maximum of two oral glucose-lowering drugs with or without basal insulin, and a body-mass index of at least 23 kg/m2. Participants were randomly assigned (1:1) subcutaneous injections once a week of either dulaglutide (1·5 mg) or an equal volume of matching placebo. Randomisation was done using a computer-generated code with stratification by site. Participants and all study personnel were masked to treatment allocation until the database was locked. Participants were followed up at least every 6 months for the composite primary outcome of stroke, myocardial infarction, or death from cardiovascular or unknown causes. Cognitive function was assessed at baseline and during follow-up using the Montreal Cognitive Assessment (MoCA) and Digit Symbol Substitution Test (DSST). We present here the exploratory primary cognitive outcome, which was the first occurrence of a follow-up score on MoCA or DSST that was 1·5 SDs or more below the baseline mean score in the participant's country. All analyses were done using an intention-to-treat approach. The REWIND trial is registered with ClinicalTrials.gov, NCT01394952. Findings Between Aug 18, 2011, and Aug 14, 2013, 9901 participants were randomly assigned to either dulaglutide (n=4949) or placebo (n=4952). During median follow-up of 5·4 (IQR 5·1–5·9) years, 8828 participants provided a baseline and one or more follow-up MoCA or DSST scores, of whom 4456 were assigned dulaglutide and 4372 were assigned placebo. The cognitive outcome occurred in 4·05 per 100 patient-years in participants assigned dulaglutide and 4·35 per 100 patient-years in people assigned placebo (hazard ratio [HR] 0·93, 95% CI 0·85–1·02; p=0·11). After post-hoc adjustment for individual standardised baseline scores, the hazard of substantive cognitive impairment was reduced by 14% in those assigned dulaglutide (HR 0·86, 95% CI 0·79–0·95; p=0·0018). Interpretation Long-term treatment with dulaglutide might reduce cognitive impairment in people with type 2 diabetes. Further studies of this drug focused on brain health and cognitive function are clearly indicated.Ciencias Médicas y de la Salud9 papplication/pdfhttps://doi.org/10.1016/S1474-4422(20)30173-3https://repositorio.udes.edu.co/handle/001/6017engElsevierReino Unido590758219ScopusThe Lancet NeurologyCopyright © 2022 The Authors, Elsevier Inc.info:eu-repo/semantics/closedAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)https://creativecommons.org/licenses/by-nc/4.0/http://purl.org/coar/access_right/c_14cbhttps://www.thelancet.com/journals/laneur/article/PIIS1474-4422(20)30173-3/fulltextEffect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trialArtículo de revistahttp://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articlehttp://purl.org/redcol/resource_type/ARTinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85Todas las AudienciasPublicationORIGINALEffect of dulaglutide on cognitive impairment in type 2 diabetes. An exploratory analysis of the REWIND trial.pdfEffect of dulaglutide on cognitive impairment in type 2 diabetes. An exploratory analysis of the REWIND trial.pdfapplication/pdf291354https://repositorio.udes.edu.co/bitstreams/0630075b-e53e-46c1-b82d-07567c382821/download4ae1ac9c0b77b7400628cf1a76b23373MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-859https://repositorio.udes.edu.co/bitstreams/76aa6b42-7e2d-4f79-bd9d-dd6efe4b1d31/download38d94cf55aa1bf2dac1a736ac45c881cMD52TEXTEffect of dulaglutide on cognitive impairment in type 2 diabetes. An exploratory analysis of the REWIND trial.pdf.txtEffect of dulaglutide on cognitive impairment in type 2 diabetes. An exploratory analysis of the REWIND trial.pdf.txtExtracted texttext/plain5https://repositorio.udes.edu.co/bitstreams/ad2405e5-1235-4488-950f-88f1d3dacbe1/download5dbe86c1111d64f45ba435df98fdc825MD53THUMBNAILEffect of dulaglutide on cognitive impairment in type 2 diabetes. An exploratory analysis of the REWIND trial.pdf.jpgEffect of dulaglutide on cognitive impairment in type 2 diabetes. An exploratory analysis of the REWIND trial.pdf.jpgGenerated Thumbnailimage/jpeg5832https://repositorio.udes.edu.co/bitstreams/efe8977c-d4fe-49ba-991f-ef9dc88a920d/download6823e8237921a10793d834cf5353bfabMD54001/6017oai:repositorio.udes.edu.co:001/60172023-10-10 08:46:12.308https://creativecommons.org/licenses/by-nc/4.0/Copyright © 2022 The Authors, Elsevier Inc.https://repositorio.udes.edu.coRepositorio Universidad de Santandersoporte@metabiblioteca.comTGljZW5jaWEgZGUgUHVibGljYWNpw7NuIFVERVMKRGlyZWN0cmljZXMgZGUgVVNPIHkgQUNDRVNPCgo= |